July 2006
Micro Caps Go Three For Three Today
July 18, 2006
Execute Sports surpassed another sales milestone, this time with flotation vests, Clearly Canadian got a cash infusion to finance advertising and operations during this peak selling season, and Novelos just started phase 2 testing of NOV-002 for treatment of ovarian cancer. In all three cases, each company...
Execute Sports surpassed another sales milestone, this time with flotation vests, Clearly Canadian got a cash infusion to finance advertising and operations during this peak selling season, and Novelos just started phase 2 testing of NOV-002 for treatment of ovarian cancer. In all three cases, each company...
June 2006
Timeless Lessons
June 23, 2006
Lately we've been focusing on our watchlist stocks with major news to discuss, but with nothing hard-hitting to look at today, we'll devote some attention to a couple of names we haven't looked at recently. This includes a detailed look at charts. Along the way, we're going to use our real-life examples...
Lately we've been focusing on our watchlist stocks with major news to discuss, but with nothing hard-hitting to look at today, we'll devote some attention to a couple of names we haven't looked at recently. This includes a detailed look at charts. Along the way, we're going to use our real-life examples...
January 2006
Feature: Tracking Novelos. Specialist or Market Maker?
January 14, 2006
Feature: Tracking Novelos. Specialist or Market Maker? Novelos (OTCBB: NVLT) came public in June 2005 at $2. The shares caught an early thermal and rose to $4.50 by late August. After two decent rallies from the $2.50 level later in the year, the shares declined to $1.53 in December and, given the volumes...
Feature: Tracking Novelos. Specialist or Market Maker? Novelos (OTCBB: NVLT) came public in June 2005 at $2. The shares caught an early thermal and rose to $4.50 by late August. After two decent rallies from the $2.50 level later in the year, the shares declined to $1.53 in December and, given the volumes...
December 2005
Feature: 2005 in Review - Beauties and the Beasts.
December 21, 2005
Feature: 2005 in Review - Beauties and the Beasts. I’m not going to belabor the fact that the Santa rally hasn’t materialized for the smallcaps this year. As a matter of fact, the fall pretty much sucked out loud for the genre. Along with some good wins, along with everyone else, we also took some lumps...
Feature: 2005 in Review - Beauties and the Beasts. I’m not going to belabor the fact that the Santa rally hasn’t materialized for the smallcaps this year. As a matter of fact, the fall pretty much sucked out loud for the genre. Along with some good wins, along with everyone else, we also took some lumps...
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study.
December 05, 2005
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study. The title of today’s release (below) from biotech Novelos Therapeutics (OTCBB: NVLT) speaks volumes: “Novelos Therapeutics Gets Green Light From FDA For Phase 3 Development in Lung Cancer”. Obviously the FDA saw the value of continuing the regulatory...
Feature: Novelos - FDA Green Lights Phase 3 Cancer Study. The title of today’s release (below) from biotech Novelos Therapeutics (OTCBB: NVLT) speaks volumes: “Novelos Therapeutics Gets Green Light From FDA For Phase 3 Development in Lung Cancer”. Obviously the FDA saw the value of continuing the regulatory...
November 2005
Feature: Novelos/FDA Meet Friday. DOW 11,000?
November 29, 2005
Feature: Novelos/FDA Meet Friday. DOW 11,000? As we mentioned on November 8th, biotech Novelos (OTCBB: NVLT) meets with the FDA on December 2nd to discuss its impressive Phase 1/2 results for its NOV-002 treatment for non-small call lung cancer (NSCLC). The company’s intention is to get the green light...
Feature: Novelos/FDA Meet Friday. DOW 11,000? As we mentioned on November 8th, biotech Novelos (OTCBB: NVLT) meets with the FDA on December 2nd to discuss its impressive Phase 1/2 results for its NOV-002 treatment for non-small call lung cancer (NSCLC). The company’s intention is to get the green light...
Feature: Novelos - FDA Meeting Soon, Radiation and the Shriners.
November 08, 2005
Feature: Novelos - FDA Meeting Soon, Radiation and the Shriners. Two recent substantive events further bolster our contention that Novelos Therapeutics (OTCBB: NVLT) deserves a place in the smallcap biotech sector of your portfolio. First, NVLT recently announced that it had been granted a meeting with...
Feature: Novelos - FDA Meeting Soon, Radiation and the Shriners. Two recent substantive events further bolster our contention that Novelos Therapeutics (OTCBB: NVLT) deserves a place in the smallcap biotech sector of your portfolio. First, NVLT recently announced that it had been granted a meeting with...
October 2005
Feature: NASDAQ Setting Up. Novelos Pullback. Coverage Changes.
October 11, 2005
Feature: NASDAQ Setting Up. Novelos Pullback. Coverage Changes. NB: Keep an eye on your email box this Friday, for a great new idea in the realm of biometrics.We think you’ll find it not only interesting but also a superior short and long-term trading opportunity. The challenging September-October market...
Feature: NASDAQ Setting Up. Novelos Pullback. Coverage Changes. NB: Keep an eye on your email box this Friday, for a great new idea in the realm of biometrics.We think you’ll find it not only interesting but also a superior short and long-term trading opportunity. The challenging September-October market...
Feature: Novelos - Research Report Calls for Significant Price Rise.
October 02, 2005
Feature: Novelos - Research Report Calls For Significant Price Rise. In a recent research report published by the Cohen Independent Research Group, the current $3.50 per share price of biotech Novelos Therapeutics (OTCBB: NVLT) could more than double over the next 12 months. And that’s at the low end...
Feature: Novelos - Research Report Calls For Significant Price Rise. In a recent research report published by the Cohen Independent Research Group, the current $3.50 per share price of biotech Novelos Therapeutics (OTCBB: NVLT) could more than double over the next 12 months. And that’s at the low end...
September 2005
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped.
September 13, 2005
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped. Investing rule number one: Every market corrects. Investing rule number two: Read rule number one. The ugly stepsister of the growing economy is the current obscene level of consumer debt in America. And what could well happen to that...
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped. Investing rule number one: Every market corrects. Investing rule number two: Read rule number one. The ugly stepsister of the growing economy is the current obscene level of consumer debt in America. And what could well happen to that...
Feature: Novelos - Use Pullback to Acquire Shares.
September 06, 2005
Feature: Novelos - Use Pullback to Acquire Shares. We strongly feel that the recent pullback in Novelos Therapeutics (OTCBB: NVLT) from $4.50 to $3.20—for no reason we can ascertain-- represents a great strategic opportunity for investors to accumulate shares or add to long-term positions. We haven’t...
Feature: Novelos - Use Pullback to Acquire Shares. We strongly feel that the recent pullback in Novelos Therapeutics (OTCBB: NVLT) from $4.50 to $3.20—for no reason we can ascertain-- represents a great strategic opportunity for investors to accumulate shares or add to long-term positions. We haven’t...
Feature: Katrina Crisis. The Economy. The Market.
September 02, 2005
Feature: Katrina Crisis. The Economy. The Market. As devastating and disturbing as the situation in the US Gulf area becomes, it will in our opinion, have limited long-term economic effect. I suggest that within a month, this unprecedented natural disaster will fade from the headlines, other than being...
Feature: Katrina Crisis. The Economy. The Market. As devastating and disturbing as the situation in the US Gulf area becomes, it will in our opinion, have limited long-term economic effect. I suggest that within a month, this unprecedented natural disaster will fade from the headlines, other than being...
August 2005
Feature: Novelos - Phase 1/2 Results Supercharge Chemotherapy.
August 08, 2005
Feature: Novelos - Phase 1/2 Results Supercharge Chemotherapy. If you or a loved one were suffering from late stage Non Small Cell Lung Cancer (NSCLC) would the administration of an inexpensive, complementary therapy that would allow more cycles of chemo and a better result than that from chemo alone...
Feature: Novelos - Phase 1/2 Results Supercharge Chemotherapy. If you or a loved one were suffering from late stage Non Small Cell Lung Cancer (NSCLC) would the administration of an inexpensive, complementary therapy that would allow more cycles of chemo and a better result than that from chemo alone...
Trading Alert: Novelos - Compounds Beat Up On Cancer and Hepatitis.
August 01, 2005
Trading Alert: Novelos - Compounds Beat Up On Cancer and Hepatitis. Before we detail the amazing potential of the cancer/hepatitis fighting therapies developed by Massachusetts-based Novelos Therapeutics (OTCBB: NVLT), we thought that as a reference, it would be of value to table our past smallcap biotech...
Trading Alert: Novelos - Compounds Beat Up On Cancer and Hepatitis. Before we detail the amazing potential of the cancer/hepatitis fighting therapies developed by Massachusetts-based Novelos Therapeutics (OTCBB: NVLT), we thought that as a reference, it would be of value to table our past smallcap biotech...
